<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949687</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 37048114.9.0000.0093</org_study_id>
    <nct_id>NCT02949687</nct_id>
  </id_info>
  <brief_title>Surgical Treatment in Diabetic Patients With Grade 1 Obesity</brief_title>
  <official_title>Duodenal Ileal Interposition With Sleeve Gastrectomy and Selective Intra-Abdominal Denervation for Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Positivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Positivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical Treatment in Diabetic Patients With Grade 1 Obesity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a randomized clinical trial, non-blind, 1-arm treatment (Duodenal Ileal&#xD;
      Interposition with Sleeve Gastrectomy and Selective Intra-Abdominal Denervation for Type 2&#xD;
      Diabetes Mellitus), including 40 research subjects with type 2 diabetes mellitus and obesity&#xD;
      class I. In order to analise the effect on weight loss and glycemic control after 2 years of&#xD;
      follow up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    investigator institution change&#xD;
  </why_stopped>
  <start_date type="Actual">September 20, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycated hemoglobin(HbA1c) level of 6.0% or less, without the use of diabetes medications</measure>
    <time_frame>2 YEARS</time_frame>
    <description>Success Rate of Biochemical Resolution of Diabetes at 24 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ileal interposition sleeve sympathectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>laparoscopic ileal interposition with sleeve and sympathectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ileal interposition with sleeve and sympathectomy</intervention_name>
    <description>laparoscopic ileal interposition with sleeve and sympathectomy</description>
    <arm_group_label>ileal interposition sleeve sympathectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of type 2 diabetes mellitus&#xD;
&#xD;
          -  Both sexes were treated with oral antidiabetic agents and / or insulin except the&#xD;
             current treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl&#xD;
             peptidase 4 inhibitors&#xD;
&#xD;
          -  Stable antidiabetic medication within the last 8 weeks prior to randomization (V2), if&#xD;
             therapy includes insulin, the average daily dose should not have changed by more than&#xD;
             10% in the past 8 weeks&#xD;
&#xD;
          -  HbA1c&gt; 8.0%&#xD;
&#xD;
          -  Age&gt; 20 years and &lt;60 years&#xD;
&#xD;
          -  Body mass index (BMI) of 30 35 kg / m²&#xD;
&#xD;
          -  Agree to sign the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus (positive for anti-GAD), or GAD negative anti anti body with&#xD;
             low β cell function (C-peptide after stimulation &lt;0.5 ng / ml)&#xD;
&#xD;
          -  Current treatment with GLP-1 receptor agonist and / or dipeptidyl peptidase 4&#xD;
             inhibitors&#xD;
&#xD;
          -  Recent vascular event (myocardial infarction, coronary angioplasty or stroke in the&#xD;
             past 6 months)&#xD;
&#xD;
          -  Malignant neoplasm&#xD;
&#xD;
          -  Portal hypertension&#xD;
&#xD;
          -  Inability to cooperate with segment&#xD;
&#xD;
          -  Low capacity of understanding surgery&#xD;
&#xD;
          -  Unrealistic expectations of the outcome&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Moderate or severe mood disorder; severe anxiety; eating disorders (based on&#xD;
             Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria)&#xD;
&#xD;
          -  Chemical dependency or alcoholism (based on DSM-V criteria).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Positivo</investigator_affiliation>
    <investigator_full_name>Luciana El-Kadre</investigator_full_name>
    <investigator_title>invited clinical professor</investigator_title>
  </responsible_party>
  <keyword>ileal interposition</keyword>
  <keyword>metabolic surgery</keyword>
  <keyword>diabetes</keyword>
  <keyword>intra abdominal selective denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

